Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Mavyret is a prescription combination antiviral containing glecaprevir and pibrentasvir. It treats acute or chronic hepatitis C virus genotypes 1 through 6 in adults and children age 3 and older without cirrhosis or with compensated cirrhosis. Tablets contain 100 mg glecaprevir and 40 mg pibrentasvir, while oral pellet packets contain 50 mg and 20 mg, respectively.
read more about mavyret ...Glecaprevir inhibits the hepatitis C virus NS3/4A protease, preventing processing of viral proteins needed for replication. Pibrentasvir inhibits the viral NS5A protein, interfering with viral RNA replication and assembly. Their combined actions suppress hepatitis C virus reproduction.
Mavyret is used in adults and children age 3 and older with qualifying hepatitis C infections, including selected previously treated patients. Treatment is restricted to patients without cirrhosis or with compensated cirrhosis. Moderate or severe hepatic impairment, any history of hepatic decompensation, and use with atazanavir or rifampin are contraindications.
Adults take three tablets together once daily with food, totaling 300 mg glecaprevir and 120 mg pibrentasvir. Children age 12 and older or weighing at least 45 kg generally use the tablet regimen. Younger children weighing less than 45 kg use weight-based oral pellet doses. Treatment-naive patients typically receive eight weeks, while some previously treated patients require 12 or 16 weeks.
Mavyret carries a boxed warning for hepatitis B virus reactivation in patients with current or previous hepatitis B infection, including cases of liver failure and death. Severe hepatic decompensation or liver failure has also occurred, particularly in patients with advanced liver disease. Testing for hepatitis B is required before treatment. Drug interactions can also cause serious adverse reactions or reduce antiviral activity.
Mavyret treats eligible acute or chronic hepatitis C infections involving genotypes 1 through 6.
Treatment-naive patients usually receive eight weeks, while selected previously treated patients require 12 or 16 weeks.
Adults take three tablets together once daily with food.
Yes. The boxed warning concerns hepatitis B reactivation, which can cause severe liver injury or death.
DailyMed - MAVYRET (glecaprevir and pibrentasvir) tablets and oral pellets. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf99777-0401-9095-8645-16c6e907fcc0. Date Accessed October 14, 2026.
Glecaprevir. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Glecaprevir. Date Accessed October 14, 2026.
Glecaprevir and Pibrentasvir. MedlinePlus. https://medlineplus.gov/druginfo/meds/a617039.html. Date Accessed October 14, 2026.
Mavyret. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548803/. Date Accessed October 14, 2026.
MAVYRET (glecaprevir and pibrentasvir) Prescribing Information. AbbVie. https://www.rxabbvie.com/pdf/mavyret_pi.pdf. Date Accessed October 14, 2026.